Virtual screening (VS) is powerful tool in discovering molecular inhibitors that are most likely to bind to drug targets of interest. Here, the authors introduce a novel VS approach, so-called ‘tailored-pharmacophore’, in order to explore inhibitors that overcome drug resistance.
Browsing: Bacterial > Tuberculosis
A new mathematical modelling study has estimated the mortality rates of TB in the pediatric population, producing the first ever estimate for infants under 5 years of age.
In this interview with Patrick Harris, from the University of Queensland, we discuss his role in setting up and co-ordinating the MERINO trial, and his research on the use of genomics in clinical microbiology.
Researchers have discovered that cell division sites in mycobacteria are correlated with inherited wave-like morphological landmarks on the cell surface.
Improved therapeutic strategies are in urgent need for better control and eradication of tuberculosis. In this editorial, the authors evaluate interleukin-37 as a new molecular target for the therapy of tuberculosis.
Researchers have uncovered metabolic changes in Mycobacterium tuberculosis, which may enable the bacteria to withstand exposure to antimicrobials, suggesting that targeting these pathways could reduce treatment times.
Helen McShane discusses her work leading the TB vaccine research program at Oxford University, and shares her thoughts on the challenges facing vaccine development and eradication of this disease.
Read our report from the second state-of-the-art symposium on nontuberculosis mycobacteria (NTM) infections covering diagnosis, biology, epidemiology and more.
In this podcast Dr Elizabeth Whittaker, Dr James Seddon, Dr Pete Dodd and Professor Beate Kampmann discuss their work in pediatric tuberculosis focusing on the areas of immunology, modelling and drug resistance.